플루드로코르티손
플루드로코르티손은 강력한 무기질코르티코이드 활성과 중등도의 당질코르티코이드 활성을 가진 합성 코르티코스테로이드입니다. 주로 개와 고양이의 **부신피질기능저하증(애디슨병)** 치료에 사용되며, 특히 승인된 주사제(데속시코르톤 피발레이트)가 적합하지 않을 때 사용됩니다. > **임상 경고:** 플루드로코르티손의 무기질코르티코이드 역가는 히드로코르티손의 약 125배이며, 당질코르티코이드 역가는 약 12배(프레드니솔론의 약 3배)입니다. 대사적 또는 신체적 스트레스가 있는 기간에는 프레드니솔론의 추가 투여가 필요할 수 있습니다.
작용 기전: Acts as an **aldosterone analogue** at the mineralocorticoid receptors in the distal convoluted tubule and collecting duct of the kidneys. * **Mineralocorticoid effect:** → Increases sodium (Na+) retention and potassium (K+) excretion. * **Glucocorticoid effect:** → Possesses roughly 3 times the glucocorticoid potency of prednisolone, contributing to anti-inflammatory and metabolic effects.
동물 종별 용량
- Hypoadrenocorticism (Addison's disease) · 0.01 mg/kg (starting dose); most stable patients require <0.05 mg/kg · PO · q12h (some may only require q24h) · Lifelong · Monitor absolute Na and K concentrations 4-6 hours post-pill. If on q24h dosing, check pre-pill concentrations as well.
- Hypoadrenocorticism (Addison's disease) · 0.01 mg/kg (starting dose); most stable patients require <0.05 mg/kg · PO · q12h · Lifelong · Doses as for dogs; very few reports in cats.
용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.
투여 경로
금기
- No specific contraindications listed in the monograph, but use with caution in patients with congestive heart failure, severe hypertension, or renal disease.
- No specific contraindications available in the monograph, but generally contraindicated in patients with systemic fungal infections or known hypersensitivity.
이상반응
- Hypertension
- Oedema (including cerebral oedema)
- Hypokalaemia
- Hypercortisolism / Iatrogenic Cushing's syndrome (with long-term overdose)
- Polyuria/polydipsia (PU/PD)
- Clinical signs of hypercortisolism (with long-term overdose)
약물 상호작용
- Amphotericin B · Increased risk of severe hypokalaemia · major
- Furosemide · Increased risk of hypokalaemia due to additive potassium-depleting effects · moderate
- Thiazide diuretics · Increased risk of hypokalaemia due to additive potassium-depleting effects · moderate
모니터링
- Absolute serum sodium concentrations
- Absolute serum potassium concentrations
- Blood pressure
- Clinical signs of hypercortisolism or hypoadrenocorticism crisis
- Body weight and hydration status
- Absolute serum sodium concentrations (4-6 hours post-pill, and pre-pill if q24h)
- Absolute serum potassium concentrations (4-6 hours post-pill, and pre-pill if q24h)
- Clinical signs of hyperadrenocorticism or hypoadrenocorticism
과용량
Overdosage can lead to **hypertension**, **oedema** (including cerebral oedema), and **hypokalaemia**. Long-term overdosage may result in clinical signs of **hypercortisolism** (iatrogenic Cushing's syndrome, e.g., PU/PD, polyphagia, alopecia, pot-bellied appearance). Treatment involves dose reduction and supportive care.
VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.